Literature DB >> 23656626

Reduction of the use of antimicrobial drugs following the rapid detection of Streptococcus agalactiae in the vagina at delivery by real-time PCR assay.

E Poncelet-Jasserand1, F Forges, M-N Varlet, C Chauleur, P Seffert, C Siani, B Pozzetto, A Ros.   

Abstract

OBJECTIVE: To assess whether the determination of the presence of group B streptococci (GBS) in the vagina using a rapid polymerase chain reaction (PCR) assay at delivery was able to spare useless antimicrobial treatments, as compared with conventional culture at 34-38 weeks of gestation.
DESIGN: Practical evaluation and prospective cost-effectiveness analysis.
SETTING: A university hospital in France. POPULATION: A cohort of 225 women in labour at the University-Hospital of Saint-Etienne.
METHODS: Each woman had a conventional culture performed at 34-38 weeks of gestation. At the beginning of labour, two vaginal swabs were sampled for rapid PCR testing and culture. The decision to prescribe a prophylactic antimicrobial treatment or not was taken according to the result of the PCR test. A comparative cost-effectiveness analysis of the two diagnostic strategies was carried out. MAIN OUTCOME MEASURES: Number of women receiving inadequate prophylactic antimicrobial drugs following each testing strategy, costs of PCR testing and culture, frequency of vaginal GBS, and diagnostic performance of the PCR test at delivery.
RESULTS: The percentage of unnecessarily treated women was significantly reduced using the rapid test versus conventional culture (4.5 and 13.6%, respectively; P < 0.001). The rate of vaginal GBS at delivery was 12.5%. The incremental cost-effectiveness ratio (ICER) for each inadequate management avoided was €36 and €173 from the point of view of the healthcare system and hospital, respectively.
CONCLUSIONS: The PCR assay reduced the number of inadequate antimicrobial treatments aimed to prevent the early onset of GBS disease. However, this strategy generates extra costs that must be put into balance with its clinical benefits.
© 2013 The Authors BJOG An International Journal of Obstetrics and Gynaecology © 2013 RCOG.

Entities:  

Keywords:  Cost-effectiveness analysis; group B streptococcus; intrapartum antimicrobial prophylaxis; real-time PCR assay

Mesh:

Substances:

Year:  2013        PMID: 23656626     DOI: 10.1111/1471-0528.12138

Source DB:  PubMed          Journal:  BJOG        ISSN: 1470-0328            Impact factor:   6.531


  4 in total

1.  Evaluation of the new brilliance GBS chromogenic medium for screening of Streptococcus agalactiae vaginal colonization in pregnant women.

Authors:  Paul O Verhoeven; Pauline Noyel; Julie Bonneau; Anne Carricajo; Nathalie Fonsale; Alain Ros; Bruno Pozzetto; Florence Grattard
Journal:  J Clin Microbiol       Date:  2014-01-08       Impact factor: 5.948

2.  Multicenter clinical evaluation of the Xpert GBS LB assay for detection of group B Streptococcus in prenatal screening specimens.

Authors:  Blake W Buchan; Matthew L Faron; DeAnna Fuller; Thomas E Davis; Donna Mayne; Nathan A Ledeboer
Journal:  J Clin Microbiol       Date:  2014-11-19       Impact factor: 5.948

Review 3.  Group B Streptococcal Neonatal Meningitis.

Authors:  Teresa Tavares; Liliana Pinho; Elva Bonifácio Andrade
Journal:  Clin Microbiol Rev       Date:  2022-02-16       Impact factor: 50.129

4.  Clinical impact of rapid polymerase chain reaction (PCR) test for group B Streptococcus (GBS) in term women with ruptured membranes.

Authors:  Enya F Fullston; Michael J Doyle; Mary F Higgins; Susan J Knowles
Journal:  Ir J Med Sci       Date:  2019-01-31       Impact factor: 1.568

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.